SCHEMBL25250554

SCHEMBL25250554

CC1(C)C(=O)NC(=O)N1c1cccc([N+](=O)[O-])c1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HPN P05981 1/20 0.54
SCN2A Q99250 1/20 0.51
TSHR P16473 2/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 4/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
ALDH1A1 P00352 1/20 0.48
PGR P06401 1/20 0.48
KDM4E B2RXH2 1/20 0.48
GAA P10253 2/20 0.47
ACHE P22303 1/20 0.46
NPC1 O15118 1/20 0.46
POLB P06746 1/20 0.46
RAB9A P51151 1/20 0.46
ABHD16A O95870 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25249887 0.76 ALDH1A1 (0.51) MEN1KMT2AALDH1A1GAAPOLB
SCHEMBL30381901 0.76 AR (0.55) MAPTMEN1KMT2AALDH1A1PGR
SCHEMBL30382173 0.76 ALDH1A1 (0.51) MEN1KMT2AALDH1A1GAAPOLB
SCHEMBL25258942 0.76 AR (0.55) MAPTMEN1KMT2AALDH1A1PGR
SCHEMBL29156606 0.74 HPN (0.53) HPNSCN2ATSHRLMNAMAPT
SCHEMBL1461676 0.74 AR (0.47) ALDH1A1GAA
SCHEMBL10338930 0.73 MGLL (0.53)
SCHEMBL5328812 0.72 HPN (0.58) HPNSCN2ATSHRLMNAMAPT
SCHEMBL4030854 0.72 AR (0.73) TSHRLMNAMAPTMEN1KMT2A
SCHEMBL2029909 0.70 HPN (1.00) HPNSCN2ATSHRLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570646-B2 Compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2026-03-10 US disclosed
CN-116033899-B Novel compounds as inhibitors of histone deacetylase 6 and pharmaceutical compositions comprising the same 株式会社 钟根堂 2024-11-05 CN disclosed
US-20230295142-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-09-21 US disclosed
US-20230295142-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-09-21 US disclosed
US-20230295142-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-09-21 US disclosed
EP-4208461-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Chong Kun Dang Pharmaceutical Corp. (KR) 2023-07-12 EP disclosed
CN-116033899-A Novel compounds as inhibitors of histone deacetylase 6 and pharmaceutical compositions comprising the same 株式会社 钟根堂 2023-04-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295142-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HDAC6, HDAC1, HDAC2 HPN 1800/4885SCN2A 1910/4885TSHR 4184/4885
US-12570646-B2 Compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same HDAC6, HDAC3, HDAC1 HPN 2747/4885SCN2A 1136/4885TSHR 1598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.